WO2017119462A1 - 抗腫瘍剤 - Google Patents
抗腫瘍剤 Download PDFInfo
- Publication number
- WO2017119462A1 WO2017119462A1 PCT/JP2017/000184 JP2017000184W WO2017119462A1 WO 2017119462 A1 WO2017119462 A1 WO 2017119462A1 JP 2017000184 W JP2017000184 W JP 2017000184W WO 2017119462 A1 WO2017119462 A1 WO 2017119462A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sulfasalazine
- pegylated
- type
- antitumor agent
- peg
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Definitions
- the present invention relates to an antitumor agent.
- CD44v is observed in many epithelial tumors, but is highly expressed in a cell population called a cancer stem cell, which is known to be particularly resistant to oxidative stress among cancer cells.
- CD44v enhances the stability of cystine transporter xCT, which is a cell surface molecule, so that CD44v is highly expressed to increase xCT expression, and as a result, uptake of cystine into the cell is promoted.
- the taken-in cystine is used for production of glutathione which is a powerful antioxidant in the cell, and the amount of glutathione in the cell is increased.
- cancer cells are said to have a high ability to cope with oxidative stress and have high resistance to treatment (Japanese Patent Application Laid-Open No. 2012-144498).
- sulfasalazine also known as salazosulfapyridine, salazopyrine, salicylazosulfapyridine
- Sulfasalazine is an acidic azo compound of sulfapyridine and 5-aminosalicylic acid (5-ASA).
- 5-ASA 5-aminosalicylic acid
- 5-ASA is the main active ingredient.
- sulfasalazine which is an unchanged form, is effective for tumors, it is considered that the antitumor effect is attenuated with conventional oral preparations. Therefore, although development as an injection such as a local injection is expected, sulfasalazine dissolves in an aqueous sodium hydroxide solution or ethanol, but hardly dissolves in water.
- an object of the present invention is to provide an antitumor agent containing water-soluble sulfasalazine as an active ingredient.
- One embodiment of the present invention is an antitumor agent comprising a water-soluble sulfasalazine as an active ingredient, wherein the water-soluble sulfasalazine is a PEG-modified sulfasalazine represented by the following formula.
- the average molecular weight of PEG modifying sulfasalazine may be 500 or more and 6000 or less, 1600 or more and 6000 or less, or 4000 or more and 6000 or less.
- the antitumor agent may be an injection.
- FIG. 2 is a dosing schedule of sulfasalazine for tumorigenic mice used in one example of the present invention.
- the average value of n is preferably 4 or more and 1136 or less, more preferably 20 or more and 227 or less, and further preferably 80 or more and 136 or less.
- the average molecular weight of the PEG that modifies sulfasalazine is not particularly limited, but the lower limit is preferably 200, more preferably 500, even more preferably 1000, and still more preferably 1600, It is more preferably 1800, further preferably 4000 or more, and further preferably 4500 or more.
- the upper limit is preferably 50000, more preferably 20000, still more preferably 10,000, still more preferably 6000, and still more preferably 5500.
- the production of PEG-modified sulfasalazine is performed by a chemical reaction between the PEG molecule terminal and sulfasalazine, but the specific method is not particularly limited, and is well known in the art. Can be done by.
- the outline of the production method is, for example, for A-type PEGylated sulfasalazine by a condensation reaction between an amino group at the PEG end and a carboxylic acid in sulfasalazine.
- the dosage form of the antitumor agent containing water-soluble sulfasalazine as an active ingredient is not particularly limited, and various dosage forms are conceivable, but it is preferably a parenteral preparation, for example, a subcutaneous injection, an intravenous injection Injection, intramuscular injection, intraperitoneal injection, etc .; transdermal administration or patch, ointment or lotion; sublingual, oral patch for buccal administration; aerosol for nasal administration; However, it is not limited to these. These preparations can be produced by known methods usually used in the preparation process.
- the drug according to the present invention may be a sustained or sustained release dosage form.
- an injection is preferable, and a local injection that can be injected in the vicinity of the tumor or into the tumor is more preferable.
- the vicinity of the tumor is preferably within about 5 cm, more preferably within about 3 cm, further preferably within about 1 cm, and within about 0.5 cm from the outer surface of the tumor mass. Further preferred.
- pH regulators, buffers, stabilizers, tonicity agents, local anesthetics, etc. to active ingredients, and manufacture injections for subcutaneous, intramuscular and intravenous using well-known techniques can do.
- examples of the pH adjuster and buffer include sodium citrate, sodium acetate, and sodium phosphate.
- Examples of the stabilizer include sodium pyrosulfite, ethylenediaminetetraacetic acid (EDTA), thioglycolic acid, and thiolactic acid.
- Examples of local anesthetics include procaine hydrochloride and lidocaine hydrochloride.
- Examples of isotonic agents include sodium chloride and glucose.
- the amount of the active ingredient contained in the drug can be appropriately determined depending on the dose range of the active ingredient and the number of times of medication.
- the dose range to be administered is not particularly limited, and the effectiveness of the contained components, the administration form, the administration route, the type of disease, the nature of the subject (such as body weight, age, medical condition and use of other drugs), and It is appropriately selected according to the judgment of the doctor in charge.
- an appropriate dose is, for example, in the range of about 0.01 ⁇ g to 100 mg, preferably about 0.1 ⁇ g to 1 mg, per kg of the subject's body weight.
- these dose modifications can be made using general routine experimentation for optimization well known in the art.
- the above dosage can be administered once to several times a day.
- FIG. 3A shows the NMR measurement results.
- FIG. 3B shows the NMR measurement results.
- Sulfasalazine has an xCT inhibitory action and, when added to cancer cells, suppresses the uptake of cystine into the cell by xCT, but xCT releases glutamate in conjunction with the uptake of cystine. Therefore, xCT inhibitory activity can be examined by examining the suppression of glutamate excretion. Therefore, in this example, the xCT inhibitory activity of PEGylated sulfasalazine was examined by measuring glutamate excretion.
- the OSC19 cell line which is a head and neck squamous cell carcinoma cell line, was 200,000 cells / well on a 6-well plate. Sowing.
- the cells adhered to the bottom of the plate, then washed twice with DMEM, sulfasalazine, PEGylated sulfasalazine (A-type PEGylated sulfasalazine: PEG2000 or PEG5000-PEGylated, and B-type PEGylated sulfasalazine: PEG5000) was replaced with 2 ml of glutamic acid-free medium containing 400 ⁇ M (as sulfasalazine). After 8 hours, the amount of glutamic acid contained in the medium was measured by absorbance using Glutamate assay kit (Abcam).
- the measured value of the glutamic acid amount was subtracted from the measured value of each medium after culturing in the drug-added medium or the drug-free medium with the absorbance measurement value of the drug-free medium itself as the background. Then, assuming that the value of no drug addition was 1, each value was obtained as a ratio and graphed (FIG. 4).
- both PEGylated with PEG2000 or PEG5000 of type A PEGylated sulfasalazine significantly suppressed glutamate excretion compared with no addition of drug.
- glutamate excretion was significantly suppressed as compared with B-type PEGylated sulfasalazine.
- A-type PEGylated sulfasalazine is slightly weaker than sulfasalazine, it has xCT inhibitory activity.
- B-type PEGylated sulfasalazine does not have xCT inhibitory activity.
- Intracellular reactive oxygen measurement Sulfasalazine has an xCT inhibitory action and, when added to cancer cells, suppresses the uptake of cystine into the cells by xCT. Cystine is converted into reduced glutathione in the cell. Since reduced glutathione has an action of suppressing an increase in the amount of active oxygen in the cell, inhibition of xCT increases the amount of active oxygen in the cell. Therefore, xCT inhibitory activity can be examined by examining the amount of active oxygen in the cell. Therefore, in this example, the xCT inhibitory activity of PEGylated sulfasalazine was examined by measuring the amount of active oxygen in the cells.
- the OSC19 cell line was seeded at 4000 cells / well in a 96-well plate using the same medium as in (3). The next day, sulfasalazine and A-type PEGylated sulfasalazine were added at 400 ⁇ M (in terms of sulfasalazine). After 24 hours, the fluorescence intensity of CM-H2DCFDA (chloromethyl derivative of H2DCFDA) was measured with a plate reader as the intracellular active oxygen level. CM-H2DCFDA reacts with hydrogen peroxide, hydroxy radicals, peroxynitrite, etc. in the cell, so that H2DCF is rapidly oxidized to produce DCF and emits fluorescence.
- CM-H2DCFDA chloromethyl derivative of H2DCFDA
- both the A-type PEGylated sulfasalazine PEGylated with PEG2000 or PEG5000 significantly increased the intracellular active oxygen level compared to the case where no drug was added.
- the intracellular active oxygen level was significantly enhanced as compared with B-type PEGylated sulfasalazine.
- A-type PEGylated sulfasalazine is slightly weaker than sulfasalazine, it increases the intracellular active oxygen level.
- B-type PEGylated sulfasalazine does not enhance intracellular reactive oxygen levels.
- the T98G cell line was seeded at 3000 cells / well in a 96-well plate. The next day, sulfasalazine and A-type PEGylated sulfasalazine were added at 0 to 1250 ⁇ M in terms of sulfasalazine concentration. Two days later, the cell viability was measured using CellTiter-Glo® (Promega). The survival rate at each concentration was determined and graphed assuming that the survival rate without addition (0 ⁇ M) was 100% (FIG. 6).
- cell viability increases with A-type PEGylated sulfasalazine (PEGylated with PEG5000), but A-type PEGylated sulfasalazine (PEGylated with PEG2000) also has cell viability equivalent to that of sulfasalazine. Have.
- the obtained aqueous solution was centrifuged at 8000 rpm for 30 minutes at room temperature, and 50 ⁇ L of the supernatant was taken. 1 ⁇ L of 5N-NaOH aqueous solution was added to the supernatant, and the UV absorption (238 nm) in the obtained aqueous solution was measured to calculate the sulfasalazine concentration (solubility in pure water and physiological saline) in the aqueous solution.
- the saturation solubility of sulfasalazine in water and physiological saline at room temperature was 0.050 mg / mL and 0.037 mg / mL, respectively, whereas PEGylated sulfasalazine was A-type At least 20.5 mg / mL and 19.1 mg / mL sulfasalazine, respectively, became soluble at room temperature.
- a cell suspension containing 1 ⁇ 10 6 OSC19 cells was implanted subcutaneously on the back of 4 week old female mice (balb / c nu / nu) to form tumors.
- Six days after transplantation when the tumor volume reached about 60 mm 3 , the 25 mice transplanted with the cells were divided into 5 groups of 5 mice, and each group was divided into A-type PEGylated sulfasalazine (PEG500, PEG1000, PEG2000, or PEG 5000), or saline.
- PEG500, PEG1000, PEG2000, or PEG 5000 A-type PEGylated sulfasalazine
- A-type PEG 500 -sulfasalazine (11.3 mg obtained by PEGylating sulfasalazine with PEG500), A-type PEG 1k -sulfasalazine (one obtained by PEGylating sulfasalazine with PEG1000) 17.6 mg, A-type PEG 2k -sulfasalazine (sulfasalazine) PEG2000 with PEG2000) 30.1 mg, A-type PEG 5k -sulfasalazine (sulfasalazine PEG5000 with PEG5000) 67.8 mg was dissolved in physiological saline to obtain 31.5 mM (in terms of sulfasalazine).
- the injection was adjusted.
- the single dose of the adjusted drug was 400 ⁇ l (250 mg / ml in terms of sulfasalazine), and the adjusted A-type PEGylated sulfasalazine injection or physiological saline was intravenously administered once every two days according to the dosing schedule of FIG. Injected.
- the total number of doses was 7 (the start date was 0 days, and 0, 2, 4, 6, 8, 10, 12 days after the start of dosing).
- the body weight of tumor-forming mice and the major axis and minor axis of the tumor observed from outside the body were measured, and the tumor volume was calculated based on the measured tumor diameter.
- FIG. 9 are graphs showing the transition of the average body weight value of each group (FIG. 8) and the transition of the average tumor volume value of each group (FIG. 9) from the start date of administration.
- PEG-modified sulfasalazine has antitumor activity regardless of the average molecular weight of PEG used for PEGylation of sulfasalazine.
- an antitumor agent containing water-soluble sulfasalazine as an active ingredient can be provided.
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
スルファサラジンを修飾しているPEGの平均分子量が500以上6000以下であってもよく、1600以上6000以下であってもよく、4000以上6000以下であってもよい。また、前記抗腫瘍剤は注射剤であってもよい。
本出願は、2016年1月6日付で出願した日本国特許出願2016-001128に基づく優先権を主張するものであり、当該基礎出願を引用することにより、本明細書に含めるものとする。
本発明の水溶性スルファサラジンを有効成分として含有する抗腫瘍剤は、下記式で表されるPEG修飾スルファサラジンである。
スルファサラジンを修飾しているPEGの平均分子量は特に限定されないが、下限は、200であることが好ましく、500であることがより好ましく、1000であることがさらに好ましく、1600であることがさらに好ましく、1800であることがさらに好ましく、4000以上であることがさらに好ましく、4500以上であることがさらに好ましい。上限は、50000であることが好ましく、20000であることがより好ましく、10000であることがさらに好ましく、6000であることがさらに好ましく、5500であることがさらに好ましい。
水溶性スルファサラジンを有効成分として含有する抗腫瘍剤の剤形は、特に限定されず、種々の剤形が考えられるが、非経口剤であることが好ましく、例えば、皮下注射剤、静脈内注射剤、筋肉内注射剤、腹腔内注射剤などの注射剤;経皮投与または貼付剤、軟膏またはローション;口腔内投与のための舌下剤、口腔貼付剤;ならびに経鼻投与のためのエアゾール剤;坐剤とすることができるが、これらには限定されない。これらの製剤は、製剤工程において通常用いられる公知の方法により製造することができる。また本発明に係る薬剤は、持続性または徐放性剤形であってもよい。
CD44v依存的に増殖するヒト大腸がん細胞HCT116を用い、KSNヌードマウスに皮下投与し、腫瘍を形成させた。10匹のマウスに細胞を移植し、5匹は、250mg/kgのスルファサラジン、5匹は100μlの生理食塩水を毎日一回腹腔内注射した。移植14日後と28日後に腫瘍径を計測し、腫瘍径に基づき重量を計算し、各群で比較した。
本実施例では、図2の上図に示すA型PEG化スルファサラジンおよび下図に示すB型PEG化スルファサラジンを合成した。
500mgのα-Methoxy-ω-amino-poly(ethylene glycol)(平均分子量:5000 Da)[日本油脂(株)、SUNBRIGHT PA (商品名)、CAS登録番号:116164-53-5]を20mLのテトラヒドロフランに溶解し、300mgのDMT-MM(4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium Chloride) [CAS登録番号:3945-69-5]、400mgのスルファサラジンと混合した後に50℃で24時間撹拌した。得られた溶液中のテトラヒドロフランを減圧留去し、10mLの0.01M塩酸にて再度懸濁した。懸濁溶液を20000×g、4℃で60分遠心処理し、上澄みを飽和塩化アンモニウム水と塩化メチレンとを用いて分液処理し、塩化メチレン層を抽出した後に溶媒を減圧留去した。得られた固形物を純水に溶解した後にPD-10カラムにて精製し、凍結乾燥することで目的物(A型PEG化スルファサラジン)として黄色粉末を得た(収量:450mg)。図3AにNMRの測定結果を示す。
300mgのα-Iodoacetamidopropyl-ω-methoxy-poly(ethylene glycol)を5mLのDMFに溶解し、さらに炭酸セシウム100mgを懸濁させた。63mgのスルファサラジンをさらに加えて、50℃にて一晩撹拌した。反応溶液をメタノールにて透析精製し、溶媒を減圧留去した後に10mLの0.01M塩酸にて再度懸濁した。懸濁溶液を20000xg、4℃で60分遠心処理し、上澄みをPD-10カラムにて精製し、凍結乾燥することで目的物(B型PEG化スルファサラジン)として黄色粉末を得た(収量:270mg)。図3BにNMRの測定結果を示す。
スルファサラジンはxCT阻害作用が有り、癌細胞に添加すると、xCTによる細胞内へのシスチンの取り込みを抑制するが、xCTはシスチンの取り込みと共役してグルタミン酸の排出を行うため、グルタミン酸の排出量抑制を調べることによって、xCT阻害活性を調べることができる。そこで、本実施例では、PEG化スルファサラジンのxCT阻害活性をグルタミン酸排出量を測定することによって調べた。
スルファサラジンはxCT阻害作用が有り、癌細胞に添加すると、xCTによる細胞内へのシスチンの取り込みを抑制する。シスチンは細胞内で還元型グルタチオンに変換される。還元型グルタチオンは、細胞内の活性酸素量の増加を抑制する作用があるため、xCTを阻害すると、細胞内の活性酸素量が上昇する。従って、細胞内の活性酸素量を調べることによって、xCT阻害活性を調べることができる。そこで、本実施例では、PEG化スルファサラジンのxCT阻害活性を細胞内の活性酸素量を測定することによって調べた。
本実施例では、A型PEG化スルファサラジン(PEG2000またはPEG5000でPEG化したもの)を用い、濃度による細胞毒性をスルファサラジンと比較した。
粉末状の10mgのスルファサラジンと25mgのA型PEG化スルファサラジン(PEG5000でPEG化したもの)を100μLの純水および生理食塩水に溶解させた。この際、室温において、スルファサラジンの不溶分が水溶液中に残存していることが確認されたため、スルファサラジンが飽和しているものと考えられた。A型PEG化スルファサラジンに関しては完全に溶解し、不溶分は存在しなかった。得られた水溶液を室温にて8000rpmで30分遠心処理し、上澄みの50μLをとった。上澄みに対して1μLの5N―NaOH水溶液を添加し、得られた水溶液におけるUV吸収(238nm)を測定することで、水溶液中のスルファサラジン濃度(純水および生理食塩水への溶解度)を算出した。
本実施例では、スルファサラジンをPEG化するために用いるPEGの平均分子量の、抗腫瘍活性に対する影響を評価した。
Claims (4)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201780013228.6A CN108697696B (zh) | 2016-01-06 | 2017-01-05 | 抗肿瘤剂 |
ES17735999T ES2863682T3 (es) | 2016-01-06 | 2017-01-05 | Agente antitumoral |
US16/067,906 US11376266B2 (en) | 2016-01-06 | 2017-01-05 | Antitumor agent |
EP17735999.9A EP3400941B1 (en) | 2016-01-06 | 2017-01-05 | Antitumor agent |
JP2017560416A JP6803589B2 (ja) | 2016-01-06 | 2017-01-05 | 抗腫瘍剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016-001128 | 2016-01-06 | ||
JP2016001128 | 2016-01-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017119462A1 true WO2017119462A1 (ja) | 2017-07-13 |
Family
ID=59274047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/000184 WO2017119462A1 (ja) | 2016-01-06 | 2017-01-05 | 抗腫瘍剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11376266B2 (ja) |
EP (1) | EP3400941B1 (ja) |
JP (1) | JP6803589B2 (ja) |
CN (1) | CN108697696B (ja) |
ES (1) | ES2863682T3 (ja) |
WO (1) | WO2017119462A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020138385A1 (en) * | 2018-12-27 | 2020-07-02 | National Cancer Center | A method for treating swi/snf complex-deficient cancers comprising glutathione (gsh) metabolic pathway inhibitor |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012144498A (ja) | 2011-01-13 | 2012-08-02 | Kinki Univ | 抗腫瘍剤 |
JP2015500334A (ja) * | 2011-12-12 | 2015-01-05 | ビーエムアイ コリア カンパニー リミテッド | 後発性白内障抑制用組成物およびその製造方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007021807A1 (en) * | 2005-08-12 | 2007-02-22 | Schering Corporation | Mcp1 fusions |
ES2771478T3 (es) * | 2013-02-18 | 2020-07-06 | Vegenics Pty Ltd | Moléculas de unión a ligando y usos de las mismas |
-
2017
- 2017-01-05 ES ES17735999T patent/ES2863682T3/es active Active
- 2017-01-05 WO PCT/JP2017/000184 patent/WO2017119462A1/ja active Application Filing
- 2017-01-05 CN CN201780013228.6A patent/CN108697696B/zh active Active
- 2017-01-05 JP JP2017560416A patent/JP6803589B2/ja active Active
- 2017-01-05 EP EP17735999.9A patent/EP3400941B1/en active Active
- 2017-01-05 US US16/067,906 patent/US11376266B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012144498A (ja) | 2011-01-13 | 2012-08-02 | Kinki Univ | 抗腫瘍剤 |
JP2015500334A (ja) * | 2011-12-12 | 2015-01-05 | ビーエムアイ コリア カンパニー リミテッド | 後発性白内障抑制用組成物およびその製造方法 |
Non-Patent Citations (3)
Title |
---|
LEUKEMIA, vol. 15, 2001, pages 1633 - 1640 |
LI ET AL.: "Current drug research on PEGylation with small molecular agents", PROGRESS IN POLYMER SCIENCE, vol. 38, 11 August 2012 (2012-08-11), pages 421 - 444, XP028982992, ISSN: 0079-6700 * |
PENDRI ET AL.: "PEG Modified Anticancer Drugs: Synthesis and Biological Activity", JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS, vol. 11, April 1996 (1996-04-01), pages 122 - 134, XP009512036, ISSN: 0883-9115 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020138385A1 (en) * | 2018-12-27 | 2020-07-02 | National Cancer Center | A method for treating swi/snf complex-deficient cancers comprising glutathione (gsh) metabolic pathway inhibitor |
JP2022515504A (ja) * | 2018-12-27 | 2022-02-18 | 国立研究開発法人国立がん研究センター | グルタチオン(gsh)代謝経路阻害剤を含むswi/snf複合体欠損がんの治療方法 |
US20220087987A1 (en) * | 2018-12-27 | 2022-03-24 | National Cancer Center | A method for treating swi/snf complex-deficient cancers comprising glutathione (gsh) metabolic pathway inhibitor |
Also Published As
Publication number | Publication date |
---|---|
US11376266B2 (en) | 2022-07-05 |
EP3400941A4 (en) | 2019-09-04 |
US20200261476A1 (en) | 2020-08-20 |
ES2863682T3 (es) | 2021-10-11 |
JP6803589B2 (ja) | 2020-12-23 |
CN108697696B (zh) | 2021-01-08 |
CN108697696A (zh) | 2018-10-23 |
JPWO2017119462A1 (ja) | 2018-11-01 |
EP3400941A1 (en) | 2018-11-14 |
EP3400941B1 (en) | 2021-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11780882B2 (en) | Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy | |
US7951780B2 (en) | Antitumor agent | |
US20050187148A1 (en) | Antitumor agent | |
TW200918099A (en) | Drug carriers | |
US10857150B2 (en) | Use of sanglifehrin macrocyclic analogues as anticancer compounds | |
US20230330021A1 (en) | Drug-loaded polymer vesicle having asymmetric membrane structure, preparation method therefor, and application thereof in preparation of drugs for treating acute myeloid leukemia | |
US20130018010A1 (en) | Polymeric conjugates of adenine nucleoside analogs | |
US20150366936A1 (en) | Inhibition of drug resistant cancer cells | |
TW201004631A (en) | Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof | |
WO2017119462A1 (ja) | 抗腫瘍剤 | |
WO2005120480A1 (ja) | 抗腫瘍効果増強剤、抗腫瘍剤及び癌治療方法 | |
CN113164474B (zh) | 维奈托克的水溶性高分子衍生物 | |
US10988429B2 (en) | Quinochalcone compound and uses thereof for treating cancer or inflammation | |
WO2014191989A1 (en) | Conjugate of a taxane and biotin and uses thereof | |
WO2009096245A9 (ja) | 医薬組成物又は組合せ剤 | |
CN103183722A (zh) | 一种乙二醛酶ⅰ抑制剂及其制备方法和医药用途 | |
CN114177177A (zh) | 一种乏氧肿瘤选择性激活前药的制备方法 | |
US20170071959A1 (en) | Novel derivatives of oxazaphosphorines and therapeutic uses thereof | |
CN107773762B (zh) | 基于pd-l1抗体偶联化疗药物的adc及其制备方法和应用 | |
JP6801908B1 (ja) | ベネトクラクスの水溶性高分子誘導体 | |
Moser et al. | Taxol inclusion complexes with a cyclodextrin dimer: possibilities to detoxify chemotherapeutics and to target drugs specifically to tumors? | |
US20240156971A1 (en) | Methods and sortilin binding conjugate compounds for targeting cancer stem cells | |
IL308098A (en) | Use of the drug to treat diseases of tumors | |
JPWO2019151320A1 (ja) | 抗がん剤 | |
US20190046653A1 (en) | Pharmaceutical Preparation Containing Camptothecin-Based Polymeric Derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17735999 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017560416 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017735999 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017735999 Country of ref document: EP Effective date: 20180806 |